Unity Biotechnology
UBX was delisted on the 8th of July, 2025.
85 hedge funds and large institutions have $109M invested in Unity Biotechnology in 2020 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 35 increasing their positions, 12 reducing their positions, and 13 closing their positions.
192% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 12
58% more capital invested
Capital invested by funds: $69.1M → $109M (+$40.3M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
46% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 13
26% more call options, than puts
Call options by funds: $594K | Put options by funds: $472K
8% more funds holding
Funds holding: 79 → 85 (+6)
0.17% more ownership
Funds ownership: 3.78% → 3.95% (+0.17%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$1.37M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.35M |
| 3 |
BlackRock
New York
|
+$863K |
| 4 |
CCM
CAAS Capital Management
New York
|
+$796K |
| 5 |
JP Morgan Chase
New York
|
+$438K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.3M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$1.02M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$361K |
| 4 |
SO
STRS Ohio
Columbus,
Ohio
|
-$293K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$262K |
UBX Hedge Fund Activity: Q4 2020 in Review
85 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Unity Biotechnology (UBX) for Q4 2020, worth a combined $109M — up 58% from $69.1M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new UBX positions and 13 closed out — a net gain of 6 holders — while 35 added to existing stakes and 12 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $1.37M. The largest seller was Fidelity Investments, cutting an estimated $1.3M.
- 85 institutional investors held Unity Biotechnology (UBX) as of Q4 2020, up from 79 in Q3 2020.
- Funds reported $109M of Unity Biotechnology stock for Q4 2020, up 58% quarter-over-quarter.
- 19 funds opened new Unity Biotechnology positions in Q4 2020 and 13 closed out, a net change of +6 holders.
- The largest Unity Biotechnology buyer in Q4 2020 was Morgan Stanley, an estimated $1.37M added.
- The largest Unity Biotechnology seller in Q4 2020 was Fidelity Investments, an estimated $1.3M sold.
Based on aggregated 13F filings for Q4 2020.